PTGX Stock Analysis: Protagonist Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 9.080m USD | 12M Return: 86.1% | US74366E1029 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 98.8M
Qual. Beats: 0
Rev. Trend: -10.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Protagonist Therapeutics (PTGX) is a US-based clinical-stage biotechnology company headquartered in Newark, California, that discovers and develops peptide-based therapeutics. Its lead programs include Icotyde, an oral peptide for moderate-to-severe plaque psoriasis, and Rusfertide, an injectable hepcidin mimetic in Phase 3 development for the rare blood disorder polycythemia vera.
The broader pipeline spans multiple therapeutic areas and includes PN-881, an oral IL-17 antagonist for immune-mediated skin diseases in Phase 1 trials, as well as earlier-stage candidates targeting obesity (PN-477, PN-458, and amylinR-based agonists), an L-4R alpha antagonist for atopic dermatitis and asthma, and PN-8047, an oral hepcidin mimetic small molecule. Founded in 2006 and listed on NASDAQ since 2016, the company operates in the biotechnology sub-industry of the healthcare sector, with a platform focused on oral and injectable peptide drug candidates across dermatology, hematology, immunology, and metabolic disease.
- Rusfertide Phase 3 data drives polycythemia vera approval timeline
- Icotrokinra psoriasis launch with J&J partnership fuels royalty revenue
- Cash position supports obesity and hematology pipeline advancement
| Net Income: 82.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 9.76 > 1.0 |
| NWC/Revenue: 273.0% < 20% (prev 271.1%; Δ 1.98% < -1%) |
| CFO/TA 0.15 > 3% & CFO 131.2m > Net Income 82.9m |
| Net Debt (-773.4m) to EBITDA (85.9m): -9.01 < 3 |
| Current Ratio: 21.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.0m) vs 12m ago 11.80% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 35.17% > 50% (prev 29.13%; Δ 6.04% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.87 (Total Current Assets 807.1m - Total Current Liabilities 37.2m) / Total Assets 885.5m |
| B: -0.34 (Retained Earnings -304.0m / Total Assets 885.5m) |
| C: 0.11 (EBIT TTM 84.3m / Avg Total Assets 801.8m) |
| D: 19.13 (Book Value of Equity 841.5m / Total Liabilities 44.0m) |
| Altman-Z'' = 25.37 = AAA |
| DSRI: 0.36 (Receivables 13.4m/28.0m, Revenue 282.0m/209.2m) |
| GMI: 0.99 (GM 98.58% / 99.57%) |
| AQI: 0.59 (AQ_t 0.08 / AQ_t-1 0.14) |
| SGI: 1.35 (Revenue 282.0m / 209.2m) |
| TATA: -0.05 (NI 82.9m - CFO 131.2m) / TA 885.5m) |
| Beneish M = -3.56 (Cap -4..+1) = AAA |
As of November 01, 2026, the stock is trading at USD 144.85 with a total of 322,545 shares traded. Over the past week, the price has changed by +4.64%, over one month by +2.75%, over three months by +4.48% and over the past year by +86.06%.
Current recommended Stop Loss: 136.60 (which is 5.7% or 1.5 ATR below the current price).
Protagonist Therapeutics has received a consensus analysts rating of 4.79. Therefore, it is recommended to buy PTGX.
- StrongBuy: 11
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 178.6 | 23.3% |
P/E Trailing = 136.233
P/E Forward = 36.9004
P/S = 32.199
P/B = 10.6419
Revenue TTM = 282.0m USD
EBIT TTM = 84.3m USD
EBITDA TTM = 85.9m USD
Long Term Debt = 6.82m USD (estimated: total debt 9.22m - short term 2.40m)
Short Term Debt = 2.40m USD (from shortTermDebt, last quarter)
Debt = 9.22m USD (from shortLongTermDebtTotal, last quarter) (leases 9.22m already included)
Net Debt = -773.4m USD (calculated: Debt 9.22m - CCE 782.6m)
Enterprise Value = 8.31b USD (9.08b + Debt 9.22m - CCE 782.6m)
Interest Coverage Ratio = unknown (Ebit TTM 84.3m / Interest Expense TTM 0.0)
EV/FCF = 62.85x (Enterprise Value 8.31b / FCF TTM 132.2m)
FCF Yield = 1.59% (FCF TTM 132.2m / Enterprise Value 8.31b)
FCF Margin = 46.87% (FCF TTM 132.2m / Revenue TTM 282.0m)
Net Margin = 29.40% (Net Income TTM 82.9m / Revenue TTM 282.0m)
Gross Margin = unknown ((Revenue TTM 282.0m - Cost of Revenue TTM 1.23m) / Revenue TTM)
Tobins Q-Ratio = 9.38 (Enterprise Value 8.31b / Total Assets 885.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.22m)
Taxrate = 1.69% (1.43m / 84.3m)
NOPAT = 82.9m (EBIT 84.3m * (1 - 1.69%))
Current Ratio = 21.71 (Total Current Assets 807.1m / Total Current Liabilities 37.2m)
Debt / Equity = 0.01 (Debt 9.22m / totalStockholderEquity, last quarter 841.5m)
Debt / EBITDA = -9.01 (Net Debt -773.4m / EBITDA 85.9m)
Debt / FCF = -5.85 (Net Debt -773.4m / FCF TTM 132.2m)
Total Stockholder Equity = 689.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.34% (Net Income 82.9m / Total Assets 885.5m)
RoE = 12.03% (Net Income TTM 82.9m / Total Stockholder Equity 689.3m)
RoCE = 12.12% (EBIT 84.3m / Capital Employed (Equity 689.3m + L.T.Debt 6.82m))
RoIC = 9.91% (NOPAT 82.9m / Invested Capital 836.7m)
WACC = 3.65% (E(9.08b)/V(9.09b) * Re(3.65%) + D(9.22m)/V(9.09b) * Rd(0.0%) * (1-Tc(0.02)))
Discount Rate = 3.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.64 | Cagr: 5.02%
[DCF] Terminal Value 77.97% ; FCFF base≈94.1m ; Y1≈107.9m ; Y5≈158.8m
[DCF] Fair Price = 48.89 (EV 2.39b - Net Debt -773.4m = Equity 3.16b / Shares 64.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.26 | # QB: 0
Revenue Correlation: -10.82 | Revenue CAGR: -12.43% | SUE: -0.23 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.66 | Chg30d=+2.37% | Revisions=+25% | Analysts=12
EPS current Year (2026-12-31): EPS=4.77 | Chg30d=-0.54% | Revisions=+40% | GrowthEPS=+332.5% | GrowthRev=+1093.1%
EPS next Year (2027-12-31): EPS=-0.10 | Chg30d=+50.15% | Revisions=+21% | GrowthEPS=-102.1% | GrowthRev=-60.8%
[Analyst] Revisions Ratio: +34% (up=22, down=10)